PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX NBTX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson…Read More
NANOBIOTIX Announces License Agreement for Worldwide Codevelopment and Commercialization of Potential FirstInClass Radioenhancer NBTXR3 Nanobiotix NASDAQNBTX
